0001104659-24-006833.txt : 20240125 0001104659-24-006833.hdr.sgml : 20240125 20240125203827 ACCESSION NUMBER: 0001104659-24-006833 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240125 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kung Winston CENTRAL INDEX KEY: 0001666963 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41929 FILM NUMBER: 24563843 MAIL ADDRESS: STREET 1: C/O PMV PHARMACEUTICALS, INC. STREET 2: 8 CLARKE DRIVE, SUITE 3 CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ArriVent Biopharma, Inc. CENTRAL INDEX KEY: 0001868279 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 BUSINESS PHONE: 240-780-6356 MAIL ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 3 1 tm244073-5_3seq1.xml OWNERSHIP DOCUMENT X0206 3 2024-01-25 0 0001868279 ArriVent Biopharma, Inc. AVBP 0001666963 Kung Winston C/O ARRIVENT BIOPHARMA, INC. 18 CAMPUS BOULEVARD, SUITE 100 NEWTOWN SQUARE PA 19073 0 1 0 0 Chief Financial Officer Stock Option (right to buy) 7.76 2034-01-03 Common Stock 197238 D The shares underlying this option vest as to 25% on January 4, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 15.21 and (ii) the exercise price of the option was multiplied by 15.21. Exhibit 24.1 - Power of Attorney /s/ James Kastenmayer, Attorney-in-Fact for Winston Kung 2024-01-25 EX-24.1 2 tm244073d5_ex24-1.htm EXHIBIT 24.1

Exhibit 24.1

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of James Paul Kastenmayer of ArriVent BioPharma, Inc. (the “Company”), the Company’s General Counsel, and John T. Rudy, Nishant Dharia, Raven Sun, Gianna M. Nappi, Elana L. Brockmann, Robyn M. Frattali and Autumn N. Mays of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly, with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

(1)

execute for and on behalf of the undersigned, in the undersigned’s capacity as a director of the Company, forms and authentication documents for EDGAR Filing Access;

(2)

do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such forms and authentication documents;

(3)

execute for and on behalf of the undersigned, in the undersigned’s capacity as a director of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

(4)

do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(5)

take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interests of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date set forth below.

Date: January 23, 2024	By:	/s/ Winston Kung
		Name: Winston Kung